Jasper Therapeutics is a biotechnology company dedicated to revolutionizing the field of stem cell and mast cell targeting for curative therapies. With a mission to provide safer and potentially curative treatments to a wider range of patients, Jasper is forging partnerships with leading academic institutions and healthcare-focused investors. Their focus lies in developing innovative therapies for diseases of mast and stem cells, as well as enhancing conditioning for monogenetic diseases and engineered stem cell therapies.

Jasper is currently studying their targeted anti-c-Kit antibody, Briquilimab, across multiple diseases. Briquilimab acts as a powerful conditioning agent for severe combined immunodeficiency, acute myeloid leukemia, myelodysplastic syndromes, Fanconi anemia, and sickle cell disease. Additionally, Jasper is exploring the potential of Briquilimab as a chronic therapeutic for patients with chronic urticaria and low to intermediate risk MDS.

By utilizing their cutting-edge Engineered Hematopoietic Stem Cells (mRNA Stem Cell Grafts), Jasper aims to overcome limitations associated with allogeneic and autologous gene-edited stem cells. Their goal is to achieve superior engraftment rates, leading to higher success rates of therapeutic transplants and more effective gene therapies. Moreover, mRNA Stem Cell Grafts have the potential to expand the availability of off-the-shelf transplants while reducing the risk of GVHD and the need for toxic conditioning.

To achieve their ambitious vision, Jasper Therapeutics boasts an experienced management team with a strong track record in drug development and commercialization. Their leadership positions them well to increase the success rates of allogeneic and gene therapy grafts, ultimately benefitting a larger patient population